Valeant shareholders vent frustrations at drugmaker’s annual meeting

Valeant shareholders vent frustrations at drugmaker’s annual meeting

LAVAL, Que. — Shareholders in Valeant Pharmaceuticals (TSX:VRX) used the company’s annual general meeting Tuesday as a forum to vent their gripes with the struggling drugmaker.

Some stockholders told CEO Joseph Papa that they were unhappy with Valeant’s low share price, insufficient response to negative media coverage and his predecessor’s lawsuit against the company seeking extra compensation.

Their frustration came after Papa said Valeant is making progress to stabilize itself after nearly two years of challenges, including a stock price that has plummeted from nearly $350 on the Toronto Stock Exchange in August 2015 to about $14 early Tuesday morning.

Papa also said Valeant has made inroads to reduce its debt, adding that he doesn’t believe its current share price reflects the efforts it has made to turn itself around.

Still, he said a proposal to change the company’s name given the negative perception tarnishing it remains under consideration.

The Canadian Press

…………………………………………………………………………………………………………….……………………………The_Quebec_Book_cover_Promo_small

Would you like to support a project based right here in Quebec?

This book is being co-authored by two people who are passionate about Quebec and everything it has to offer. One of the authors moved to the region some years ago while the other was born and raised in Quebec.

The Québec Book is a unique guide for anyone interested in learning about Quebec culture and the language spoken here. You could be someone visiting Québec, planning to move to Québec, or already living here. Or maybe you’re a native English speaker, a native French speaker, or a speaker of any other language for that matter.

Pre-Order The Québec Book Now and Receive a Bonus!

Categories: Business

About Author

Write a Comment

Only registered users can comment.